Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients

Journal of Clinical Oncology

Volumn 21, Issue 22, 2003, Pages 4235-4238

  Marec Berard, Perrine ^a   Blay, Jean Yves ^a   Schell, Matthias ^a   Buclon, Murielle ^a   Demaret, Corrine ^a   Ray Coquard, Isabelle ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; HEMOGLOBIN A;

ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; ADOLESCENT; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; FEMALE; HOSPITALIZATION; INFANT; LEUKOCYTE COUNT; MALE; NEOPLASM; PREDICTION AND FORECASTING; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN A; HUMANS; INFANT; LEUKOCYTE COUNT; MALE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0642378072     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.121     Document Type: Article

References (21)

1. Michon J: Incidence of anemia in pediatric cancer patients in Europe: Results of a large, international survey. Med Pediatr Oncol 39:448-450, 2002
2. Ray-Coquard I, Le Cesne A, Rubio MT, et al: Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens: The Elypse 1 Study Group. J Clin Oncol 17:2840-2846, 1999
3. Lansky SB, List MA, Lansky LL, et al: The measurement of performance in childhood cancer patients. Cancer 60:1651-1656, 1987
4. Verger E, Salamero M, Conill C: Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 28:1328-1330, 1992
5. Ludwig H: Anemia of hematologic malignancies: What are the treatment options? Semin Oncol 29:45-54, 2002
6. Estrin JT, Schocket L, Kregenow R, et al: A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 4:318-324, 1999
7. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 91:2214-2221, 2001
8. Ludwig U, Pecorelli S: Suboptimal hemoglobin levels: Do they impact patients and their therapy? Audience responses. Semin Oncol 27:18-19, 2000
9. Skillings JR, Sridhar FG, Wong C, et al: The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study. Am J Clin Oncol 16:22-25, 1993
10. Del Mastro L, Venturini M, Lionetto R, et al: Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15:2715-2721, 1997
11. Fein DA, Lee WR, Hanlon AL, et al: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13:2077-2083, 1995
12. Hensley ML, Lebeau D, Leon LF, et al: Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer. Gynecol Oncol 81:485-489, 2001
13. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
14. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
15. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study-Procrit Study Group. J Clin Oncol 16:3412-3425, 1998
16. Beck MN, Beck D: Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 25:17-21, 1995
17. Bolonaki I, Stiakaki E, Lydaki E, et al: With recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 13:111-121, 1996
18. Leon P, Jimenez M, Barona P, Sierrasesumaga L: Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol 30:110-116, 1998
19. Csaki C, Ferencz T, Schuler D, Borsi JD: Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 34:364-367, 1998
20. Henze G, Michon J, Morland B, et al. Phase III randomized study: Efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 21:387, 2002 (abstr 1547)
21. Corazza F, Beguin Y, Bergmann P, et al: Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood 92:1793-1798, 1998